IBD: Crohn's Disease
Have you been switched/transitioned to a biosimilar version of Remicade® (infliximab)?
BC PharmaCare coverage is changing for people who take Remicade® (infliximab) for the treatment of Crohn’s disease or ulcerative colitis.
In light of this, CDHF wants to understand the recent experiences of people living in Canada who have switched/transitioned from Remicade® (infliximab) to the biosimilar versions of infliximab: Inflectra® and Renflexis™.
If you haven’t been asked to switch/transition yet, please note that we will keep this survey open for a few months so you can come back to it and complete it.This survey is only for people living in the Canada, aged 18+ who have switched/transitioned from the biologic Remicade to the biosimilar Inflectra® or Renflexis™.
The final anonymous results will be shared with health care professionals, and the public.
- If you have any questions, please email Kelsey@CDHF.ca
- To find out more about the BC Biosimilars Initative: Phase Two, visit our information page here.